Market Analysis: Global Gastrointestinal Diseases Drug Development Market

Global gastrointestinal diseases drug development market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of gastrointestinal disorders worldwide and pharmaceuticals companies operating in gastrointestinal diseases pipeline space are the key factors for market growth.

Key Market Players:

Few of the major competitors currently working in the global gastrointestinal diseases drug development market are Kyowa Kirin Co., Ltd, Ardelyx, Shanghai Fosun Pharmaceutical (Group）Co., Ltd., RedHill, GlaxoSmithKline plc, Avexegen Therapeutics, Inc., Knight Therapeutics Inc., Daewon Pharmaceutical Co., Ltd, Metacrine, Vaxart, Inc, Takeda Pharmaceutical Company Limited, SynAct Pharma AB, Sequella, Inc, Prometic Life Sciences Inc, SHIELD THERAPEUTICS, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Abbott, F. Hoffmann-La Roche Ltd, Pfizer Inc, ABIVAX among others

Market Definition: Global Gastrointestinal Diseases Drug Development Market

Gastrointestinal diseases are defined as the condition or disease that occurs within the gastrointestinal tract. The gastrointestinal disorders includes constipation, irritable bowel syndrome, colitis, inflammatory bowel disease and hence forth. The patients with gastrointestinal disorders may experience abdominal pain and cramps, bloating and change in bowel habits.

According to the articles published in the Oxford University Press by Journal of the Canadian Association of Gastroenterology, it was estimated up to 270,000 patients are living with inflammatory bowel disease and 135,000 patients with Crohn’s disease in the Canada in the year of 2018. These growing cases of gastrointestinal diseases and high demand of disease specific treatment are factors to drive the market growth.

Market Drivers

Introduction of biologics for the treatment of gastrointestinal diseases is boosting the gastrointestinal diseases drug development market
High prevalence of gastrointestinal disorders worldwide will drive the market growth
On-going clinical trial is being conducted by the many pharmaceuticals companies also acts as a market driver
New launches of products annually is propelling the market growth

Market Restraints

Huge expenditure involved in research and development will restrict the market growth
Patent expiry of major drugs and introduction of generic drugs of branded version is expected to hamper the market growth
Limited success rate of novel therapies will hamper the market growth

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gastrointestinal-diseases-drug-development-market

Segmentation: Global Gastrointestinal Diseases Drug Development Market

By Disease Type

Gastroenteritis
Inflammatory bowel disease (IBD)
Irritable bowel syndrome
Others

By Molecular targets

Sodium Transporter Nhe3 Inhibitor
Sphinogosine-1-Phosphate Receptor Functional Antagonist
Tumor Necrosis Factor (TNF) Blocker
Others

By Marketed Drugs

Infliximab
Adalimumab
Mesalazine
Others

By Clinical Trials

Etrolizumab
SHP647
ABX464
ASP3291
Others

By Route of Administration

Oral
Injectable

 By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Geography

North America
U.S.
Canada
Mexico
South America
Brazil
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-gastrointestinal-diseases-drug-development-market

Key Developments in the Market:

In June 2019, Knight Therapeutics Inc, filed New Drug Submission (NDS) to the Health Canada for Ibsrela, (tenapanor), an oral sodium transporter NHE3 inhibitor for the treatment of irritable bowel syndrome in patients with constipation. Upon approval of Ibsrela, it will change the treatment landscape to the physician as well as patients suffering from irritable bowel syndrome throughout the Canada
In November 2018, Ardelyx received FDA’s acceptance of New Drug Application (NDA) for Tenapanor, sodium transporter NHE3 inhibitor for the treatment of irritable bowel syndrome in patients with constipation. If approved it will shift from standard symptomatic treatment to the disease specific treatment

Competitive Analysis:

Global gastrointestinal diseases drug development market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global gastrointestinal diseases drug development market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.